ClinicalTrials.gg
CompletedNCT01084174Updated Apr 7, 2017Results posted

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

A Phase 1/2 interventional study of Peanut powder and Peanut extract in Peanut Hypersensitivity, Food Hypersensitivity and Immediate Hypersensitivity, sponsored by Johns Hopkins University. Completed at 1 site in United States. Open to participants aged 6 Years to 21 Years. Per ClinicalTrials.gov, last updated 2017-04-07.

Sponsored by Johns Hopkins University · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
6 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing peanut in Peanut Hypersensitivity — none open to participants now, 1 under way, none of them phase 3. peanut · Peanut Hypersensitivity.

Enrollment
6th of 13
21 · median 20
Started
2010
with 1 other
Phase 1/2
5 of 13
none open now
Registered
4th of 13
by date
Lead sponsor
1 of 13
Johns Hopkins University

Among the 13 studies testing peanut in Peanut Hypersensitivity, this one is the 6th largest by enrollment, is one of 2 that started in 2010, is one of 5 in phase 1/2, and was the 4th registered.

Peanut Hypersensitivity

166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.

Browse Peanut Hypersensitivity studies →

Open to participants now

None of the 13 studies testing peanut in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →

Where they have run

About peanut

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.

This study: 6 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing peanut in Peanut Hypersensitivity as a file.
02

Study summary

The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.

Read the detailed description

To effectively address the Primary Objectives of this pilot study, 30 subjects aged 6-21 years with: (1) a convincing clinical history of peanut allergy (PA), (2) a serum immunoglobulin E (IgE) specific to peanut of >0.35 kilo units per liter (kU/L) and a skin prick test (SPT) wheal >3 mm, will be enrolled. Subjects will be recruited from the Johns Hopkins Pediatric Allergy Clinic.

Participants will undergo an initial screening visit that will include a medical history, physical exam, skin testing, and phlebotomy. Informed consent and assent will be obtained. At the next two visits, 20 participants will complete a double-blind placebo-controlled food challenge (DBPCFC). Eligible subjects will be randomized in a 1:1 ratio into two groups. One group will receive active SLIT with placebo OIT and the other group will begin active OIT with placebo SLIT dose escalation. Over the next 16 weeks of the study, subjects will undergo SLIT and OIT dose increases. A maintenance dose will then be taken at home daily for 12 months. A DBPCFC will be completed after 6 months and 12 months of home dosing. Those patients who pass the DBPCFC will be taken off SLIT and OIT for 4 weeks. A final challenge will be administered at the end of this period.

Ten additional peanut-allergic subjects age 6-21 years will be enrolled and followed as longitudinal controls for the mechanistic studies. These subjects will follow a modified schedule compared to those subjects receiving study treatment and will be evaluated by phlebotomy, end point titration prick skin testing, and saliva collection. These patients will continue strict avoidance of peanut unless otherwise advised by their personal physician.

03

Conditions studied

  • Peanut Hypersensitivity
  • Food Hypersensitivity
  • Immediate Hypersensitivity

Keywords

  • Peanut Allergy
04

Who can participate

Ages eligible
6 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are ages 6 to 21 years of either sex, any race, and any ethnicity at the time of the initial visit.
  • Have a physician diagnosed peanut allergy or a convincing clinical history of peanut allergy (urticaria, upper or lower respiratory symptoms, GI disturbances, rash or oral symptoms).
  • Have a skin prick test positive to peanut (diameter of wheal 3 mm ≥ negative control) and detectable serum peanut-specific IgE level (UniCAP ≥ 0.35 kU/L).
  • Have a positive reaction to a cumulative dose of ≤1,000 mg of peanut powder in the initial qualifying DBPCFC.
  • Use an effective method of by females of to prevent pregnancy and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
  • Ability to perform spirometry maneuvers in accordance with the American Thoracic Society (ATS) guidelines (1994).
  • Have self-injectable epinephrine (i.e. EpiPen® or EpiPen Jr.®) available at all times.
  • Provide signed (by parent or legal guardian if the subject is a minor) and informed assent if applicable.

Exclusion criteria

Exclusion Criteria:

  • Have a history of severe anaphylaxis to peanut with hypoxia (cyanosis or peripheral capillary oxygen saturation (SpO2) ≤92% at any stage), hypotension or neurological compromise (confusion, collapse, loss of consciousness or incontinence).
  • Tolerates more than 1,000 mg of peanut powder at the initial qualifying DBPCFC.
  • Have a viral upper respiratory infection (URI) or gastroenteritis within 7 days of OFC (OFC will need to be rescheduled).
  • Currently participating in a study using an new drug.
  • Participation in any interventional study for the treatment of food allergy in the past 12 months.
  • Pregnancy or lactation
  • Allergy to placebo ingredients (Glycerin or oat flour) OR reacts to any dose of placebo during the qualifying OFC.
  • Currently in a buildup phase of any allergy immunotherapy.
  • Poor control of atopic dermatitis.
  • Have pulmonary function tests with forced expiratory volume 1 () value \<80% predicted or any clinical features of greater than moderate persistent asthma and greater than high daily doses of inhaled (>500µg/day fluticasone or equivalent).
  • Use of steroid medications (oral steroids, such as prednisone or Medrol, steroid injections, such as Kenalog, or IV or oral corticosteroid burst) in the following manners:

    o History of daily oral steroid dosing within 4 weeks prior to baseline visit or for > 1 month during the past year or burst oral steroid course in the past 6 months or > 1 burst oral steroid course in the past year.

  • Asthma requiring

    • ≥1 hospitalization in the past year for asthma or
    • >1 ER visit in the past 6 months for asthma
  • Use of omalizumab or other non-traditional forms of allergen immunotherapy (e.g., oral or sublingual) or immuno-modulatory therapy (not including corticosteroids) or biologic therapy within the past year.
  • Use of β-blockers (oral), angiotensin-converting enzyme (ACE) inhibitors, angiotensin-receptor blockers (ARB), calcium channel blockers or tricyclic antidepressant therapy.
  • Inability to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or OFC's.
  • History of alcohol or drug abuse.
  • Active eosinophilic gastrointestinal disease in the past two years.
  • Have other significant medical conditions (e.g., liver, gastrointestinal, kidney, cardiovascular, pulmonary disease, or blood disorders) which, in the opinion of the Investigator, make the subject unsuitable for induction of food reactions.
  • Any previous intubation due to allergies or asthma.
  • Severe reaction at initial DBPCFC, defined as:

    • Life-threatening anaphylaxis
    • Requiring overnight hospitalization
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Active SLIT/Placebo OIT

    These subjects will receive peanut powder given orally and placebo extract given sublingually.

    Drug: Peanut powder · Drug: Placebo extract

  • Experimental
    Active OIT/Placebo SLIT

    These subjects will receive peanut extract given sublingually and placebo powder given orally.

    Drug: Peanut extract · Drug: Placebo powder

Interventions

  • Delivered orally

  • DrugPeanut extract

    Delivered sublingually

  • DrugPlacebo extract

    Delivered sublingually

  • DrugPlacebo powder

    Delivered orally

06

What researchers measure

Primary outcomes

  1. Number of Participants With Induced Peanut Desensitization at 12 Months

    Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.

    Time frame: 12 months

Secondary outcomes

  1. Between Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)

    Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)

    Time frame: Baseline and end of dose build-up (up to 16 weeks)

  2. Between Arm Change in IgG4 From Baseline to 6 Months

    IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months

    Time frame: Baseline and 6 months

  3. Between Arm Change in IgG4 From Baseline to 12 Months

    IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months

    Time frame: Baseline and 12 months

  4. Between Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)

    Time frame: Baseline to end of dose build-up (up to 16 weeks)

  5. Between Arm Change in IgE From Baseline to 6 Months

    Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months

    Time frame: Baseline and 6 months

  6. Between Arm Change in IgE From Baseline to 12 Months

    IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months

    Time frame: Baseline and 12 months

07

Results

Posted Apr 7, 2017

Participant flow

Participant flow — Overall Study
MilestoneActive SLIT/Placebo OITActive OIT/Placebo SLIT
Started1011
Completed97
Not completed14
Withdrew: Gastrointestinal symptoms11
Withdrew: Eosinophilic esophagitis01
Withdrew: Anaphylaxis01
Withdrew: Participant noncompliance01

Outcome measures

PrimaryNumber of Participants With Induced Peanut Desensitization at 12 Months

Peanut desensitization was defined as a greater than 10-fold increase in oral food challenge (OFC) threshold after 12 months of therapy.

Time frame:
12 months
Reported as:
Count of participants · Participants
Number of Participants With Induced Peanut Desensitization at 12 Months
ParticipantsActive SLIT/Placebo OITActive OIT/Placebo SLIT
Number of Participants With Induced Peanut Desensitization at 12 Months97
SecondaryBetween Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)

Serum immunoglobulin G4 (IgG4) levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at the end of dose build-up (up to 16 weeks)

Time frame:
Baseline and end of dose build-up (up to 16 weeks)
Reported as:
Median · mga/L
Between Arm Change in IgG4 From Baseline to End of Dose Build-up (up to 16 Weeks)
mga/LActive SLIT/Placebo OITActive OIT/Placebo SLIT
Baseline0.9 (0.19 to 1.76)1.3 (0.22 to 5.89)
End of dose build-up (up to 16 weeks)2.5 (0.47 to 7.07)11.3 (0.99 to 58.7)
Statistical analysis
  • Active SLIT/Placebo OIT vs Active OIT/Placebo SLIT · Regression, Linear · p = .003Analyzed by linear regression models using generalized estimating equations to account for repeated measures over time with robust standard errors
SecondaryBetween Arm Change in IgG4 From Baseline to 6 Months

IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 6 months

Time frame:
Baseline and 6 months
Reported as:
Median · mga/L
Between Arm Change in IgG4 From Baseline to 6 Months
mga/LActive SLIT/Placebo OITActive OIT/Placebo SLIT
Baseline0.9 (0.19 to 1.76)1.3 (0.22 to 5.89)
6 months7.9 (1.51 to 76.2)83.4 (21.2 to 677)
Statistical analysis
  • Active SLIT/Placebo OIT vs Active OIT/Placebo SLIT · Regression, Linear · p = <.001
SecondaryBetween Arm Change in IgG4 From Baseline to 12 Months

IgG4 levels are measured in milligrams of Antibody per liter (mga/L) and were collected at baseline and at 12 months

Time frame:
Baseline and 12 months
Reported as:
Median · mga/L
Between Arm Change in IgG4 From Baseline to 12 Months
mga/LActive SLIT/Placebo OITActive OIT/Placebo SLIT
Baseline0.9 (0.19 to 1.76)1.3 (0.22 to 5.89)
12 months8.5 (2.42 to 69.1)76 (28.8 to 1790)
Statistical analysis
  • Active SLIT/Placebo OIT vs Active OIT/Placebo SLIT · Regression, Linear · p = <.001
SecondaryBetween Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)
Time frame:
Baseline to end of dose build-up (up to 16 weeks)
Reported as:
Mean · kUa/L
Between Arm Change in IgE From Baseline to End of Dose Build-up (up to 16 Weeks)
kUa/LActive SLIT/Placebo OITActive OIT/Placebo SLIT
Baseline163 (37.5 to 746)169 (35.1 to 716)
End of dose build-up (up to 16 weeks)369 (47.4 to 1960)392 (84 to 1069)
Statistical analysis
  • Active SLIT/Placebo OIT vs Active OIT/Placebo SLIT · Regression, Linear · p = 0.40
SecondaryBetween Arm Change in IgE From Baseline to 6 Months

Serum immunoglobulin E (IgE) levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 6 months

Time frame:
Baseline and 6 months
Reported as:
Median · kUa/L
Between Arm Change in IgE From Baseline to 6 Months
kUa/LActive SLIT/Placebo OITActive OIT/Placebo SLIT
Baseline163 (37.5 to 746)169 (35.1 to 716)
6 months387 (34.1 to 1032)68 (50.9 to 204)
Statistical analysis
  • Active SLIT/Placebo OIT vs Active OIT/Placebo SLIT · Regression, Linear · p = .07
SecondaryBetween Arm Change in IgE From Baseline to 12 Months

IgE levels are measured in kilo units of Antibody per liter (kUa/L) and were collected at baseline and at 12 months

Time frame:
Baseline and 12 months
Reported as:
Median · kUa/L
Between Arm Change in IgE From Baseline to 12 Months
kUa/LActive SLIT/Placebo OITActive OIT/Placebo SLIT
Baseline163 (37.5 to 746)169 (35.1 to 716)
12 months273 (21.0 to 1111)53 (32.4 to 82.9)
Statistical analysis
  • Active SLIT/Placebo OIT vs Active OIT/Placebo SLIT · Regression, Linear · p = .007

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Active SLIT/Placebo OIT0/4,578 (0%)0/4,578 (0%)416/4,578 (9.1%)
Active OIT/Placebo SLIT0/4,049 (0%)0/4,049 (0%)1,736/4,049 (42.9%)
Most frequent other events
Most frequent other events
EventActive SLIT/Placebo OITActive OIT/Placebo SLIT
Gastrointestinal symptomsGastrointestinal disorders325/45781344/4049
Respiratory SymptomsRespiratory, thoracic and mediastinal disorders27/4578279/4049
skin symptomsSkin and subcutaneous tissue disorders64/4578113/4049

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Active SLIT/Placebo OITActive OIT/Placebo SLITTotal
<=18 years101121
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Active SLIT/Placebo OITActive OIT/Placebo SLITTotal
Female6410
Male4711
Region of Enrollment
Region of Enrollment(participants)Active SLIT/Placebo OITActive OIT/Placebo SLITTotal
United States101121
Prior history of peanut anaphylaxis
Prior history of peanut anaphylaxis(Participants)Active SLIT/Placebo OITActive OIT/Placebo SLITTotal
Count of participants167
Other food allergies
Other food allergies(Participants)Active SLIT/Placebo OITActive OIT/Placebo SLITTotal
Count of participants101020
Atopic dermatitis
Atopic dermatitis(Participants)Active SLIT/Placebo OITActive OIT/Placebo SLITTotal
Count of participants6612
08

Study locations

1 site
  • Johns Hopkins University
    Baltimore, Maryland 21287-3923, United States
09

References and documents

Publications

  • Narisety SD, Frischmeyer-Guerrerio PA, Keet CA, Gorelik M, Schroeder J, Hamilton RG, Wood RA. A randomized, double-blind, placebo-controlled pilot study of sublingual versus oral immunotherapy for the treatment of peanut allergy. J Allergy Clin Immunol. 2015 May;135(5):1275-82.e1-6. doi: 10.1016/j.jaci.2014.11.005. Epub 2014 Dec 18. PubMed 25528358 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2010, a primary completion of Jan 2012 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 5 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2010
First posted
Mar 10, 2010
Start
Mar 2010
Primary completionActual
Jan 2012
CompletionActual
Jan 2013
Results first posted
Apr 7, 2017
Last update
Apr 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01084174
Responsible party
Sponsor
First posted
Mar 10, 2010
Start date
Mar 2010
Primary completion
Jan 2012
Completion
Jan 2013
Results posted
Apr 7, 2017
Last update
Apr 7, 2017

Study contacts

Robert Wood, MD
principal investigator · Johns Hopkins University

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peanut

Start the discussion